BioCentury
ARTICLE | Clinical News

AVX-001: Phase I/IIa data

July 20, 2015 7:00 AM UTC

A double-blind, dose-escalation Phase I/IIa trial in 26 patients with mild to moderate psoriasis showed that topical AVX001 for 4 weeks significantly reduced psoriasis plaque thickness vs. placebo. Th...